28.15
2.51%
+0.69
Genmab ADR stock is currently priced at $28.15, with a 24-hour trading volume of 339.61K.
It has seen a +2.51% increased in the last 24 hours and a -8.69% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $27.56 pivot point. If it approaches the $28.07 resistance level, significant changes may occur.
Previous Close:
$27.46
Open:
$28.09
24h Volume:
339.61K
Market Cap:
$18.26B
Revenue:
$2.39B
Net Income/Loss:
$634.20M
P/E Ratio:
28.09
EPS:
1.0022
Net Cash Flow:
$1.02B
1W Performance:
-1.92%
1M Performance:
-8.69%
6M Performance:
-0.49%
1Y Performance:
-31.07%
Genmab ADR Stock (GMAB) Company Profile
Name
Genmab ADR
Sector
Industry
Phone
45 70 20 27 28
Address
Kalvebod Brygge 43, Copenhagen
Genmab ADR Stock (GMAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
Dec-06-23 | Upgrade | UBS | Neutral → Buy |
Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Aug-24-23 | Initiated | BTIG Research | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
May-31-23 | Initiated | UBS | Neutral |
May-12-23 | Initiated | Morgan Stanley | Underweight |
Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
Nov-14-22 | Initiated | William Blair | Mkt Perform |
Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
May-02-22 | Initiated | Cowen | Market Perform |
Mar-16-22 | Upgrade | UBS | Neutral → Buy |
Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
Dec-01-21 | Initiated | Berenberg | Sell |
Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-20-21 | Initiated | Deutsche Bank | Buy |
Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
Apr-23-20 | Initiated | Credit Suisse | Outperform |
Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
Jan-13-20 | Initiated | SunTrust | Buy |
Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-12-19 | Initiated | Guggenheim | Buy |
Aug-12-19 | Initiated | Morgan Stanley | Overweight |
Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab ADR Stock (GMAB) Latest News
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Zacks Investment Research
Analyst Ratings For Genmab
Benzinga
4 Analysts Assess Genmab: What You Need To Know
Benzinga
Cracking The Code: Understanding Analyst Reviews For Genmab
Benzinga
What's Going On With Danish Healthcare Firm Genmab Stock?
Benzinga
New Strong Buy Stocks for January 17th
Zacks Investment Research
Genmab ADR Stock (GMAB) Financials Data
Genmab ADR (GMAB) Revenue 2024
GMAB reported a revenue (TTM) of $2.39 billion for the quarter ending December 31, 2023, a +17.78% rise year-over-year.
Genmab ADR (GMAB) Net Income 2024
GMAB net income (TTM) was $634.20 million for the quarter ending December 31, 2023, a -16.67% decrease year-over-year.
Genmab ADR (GMAB) Cash Flow 2024
GMAB recorded a free cash flow (TTM) of $1.02 billion for the quarter ending December 31, 2023, a +99.53% increase year-over-year.
Genmab ADR (GMAB) Earnings per Share 2024
GMAB earnings per share (TTM) was $0.9622 for the quarter ending December 31, 2023, a -16.59% decline year-over-year.
About Genmab ADR
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Cap:
|
Volume (24h):